Stanley Druckenmiller Regeneron Pharmaceuticals, Inc. Transaction History

Duquesne Family Office LLC

  • $2.95 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021
SELL
$478.3 - $607.98 $17 Million - $21.6 Million
-35,582 Closed
0 $0
Q3 2020

Nov 16, 2020
SELL
$544.75 - $658.21 $1.7 Million - $2.05 Million
-3,118 Reduced 8.06%
35,582 $19.9 Million
Q2 2020

Aug 14, 2020
BUY
$493.32 - $643.92 $19.1 Million - $24.9 Million
38,700 New
38,700 $24.1 Million
Q4 2017

Feb 14, 2018
SELL
$358.63 - $469.95 $11.4 Million - $14.9 Million
-31,800 Closed
0 $0
Q3 2017

Nov 14, 2017
BUY
$431.38 - $504.0 $13.7 Million - $16 Million
31,800
31,800 $14.2 Million

Others Institutions Holding REGN

# of Institutions
1,529
Shares Held
84.1M
Call Options Held
1.22M
Put Options Held
1.51M
View Full List

About REGENERON PHARMACEUTICALS, INC.

REGN Quotes by TradingView
  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track Stanley Druckenmiller's Portfolio

Track Stanley Druckenmiller Portfolio

Follow Stanley Druckenmiller (Duquesne Family Office LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Duquesne Family Office LLC, based on Form 13F filings with the SEC.

News

Stay updated on Duquesne Family Office LLC and Stanley Druckenmiller with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email